Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Zeo ScientifiX ( (ZEOX) ) is now available.
On July 9, 2025, ZEO ScientifiX announced an expansion initiative in response to Florida’s new SB-1768 stem cell law, which allows the use of non-FDA-approved stem cell therapies. The company launched a new website and formed agency partnerships to address the anticipated demand in the biologics market. ZEO aims to lead the market with its proprietary biologics platform, educational initiatives, and compliance focus, positioning itself as a key player in the emerging regenerative medicine market in Florida and potentially other states.
More about Zeo ScientifiX
ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics. The company is committed to advancing regenerative medicine and biologic therapeutics, offering proprietary products such as Zofin™ and Patient Pure X™. These products are manufactured in an FDA-registered, cGMP-compliant laboratory, with a focus on setting industry standards and educating physicians to improve patient care.
Average Trading Volume: 6,413
Technical Sentiment Signal: Hold
Current Market Cap: $12.84M
Learn more about ZEOX stock on TipRanks’ Stock Analysis page.